Merck Announces 2016 Grant for Growth Innovation Winners

Merck (Darmstadt, Germany, known as EMD Serono in the US) this week announced the recipients of the Grant for Growth Innovation (GGI) at an award presentation European Society for Pediatric Endocrinology (ESPE) Meeting in Paris, France.   The GGI program was initiated to support the advancement of understanding of the field of growth. A total grant of up to €400,000 per year, divided between up to three research proposals, is awarded to the selected projects.    This year's winning projects are based in Australia, Italy, and Brazil, and are as follows:

• Andrew J. Brooks
  University of Queensland Diamantina Institute, Brisbane, Australia
  Project: Targeting the transmembrane domain of the growth hormone receptor to develop new drug classes addressing unmet needs in treatment of growth hormone disorders.

• Antonio Cittadini, MD, PhD
  Federico II University, Naples, Italy
  Project: Treatment of growth hormone deficiency associated with chronic heart failure: A randomized, double-blind, placebo-controlled study.

• Alexander Augusto de Lima Jorge, MD, PhD
  University of São Paulo Medical School, Brazil
  Project: Growth hormone and estrogen pharmacogenetics in patients with Turner syndrome.

    For further information about the GGI and how to apply for next year's grants, please visit

http://www.grantforgrowthinnovation.org